AIM ImmunoTech Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
AIM ImmunoTech Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Ampligen in Chronic Fatigue Syndrome | Myalgic Encephalomyelitis (Phase 3).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Poly I: Poly C12U (Rintatolimod) | Chronic Fatigue Syndrome | n/a | n/a | Public pipeline row |
| Rintatolimod | Pancreatic Cancer | n/a | Phase 2 | Public pipeline row |
| poly I-poly C12U | HIV Seropositivity | HIV Infection | n/a | Phase 2 | Public pipeline row |
| Ampligen | Chronic Fatigue Syndrome | Myalgic Encephalomyelitis | n/a | Phase 3 | Public pipeline row |
| Durvalumab | Metastatic Pancreatic Cancer | Antibody | Phase 1 | Phase 2 | Public pipeline row |
| Cisplatin + celecoxib + DC vaccine | n/a | Vaccine | Phase 1 | Phase 2 | Public pipeline row |
| Chemokin Modulatory Regimen (5 MU/m2) | Colorectal Cancer | Colorectal Carcinoma | Colorectal Tumors | Neoplasms, Colorectal | n/a | Phase 1 | Phase 2 | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT00215800 | Phase 3 | COMPLETED | 234 | 2004-02 |
| NCT00035581 | Phase 2 | TERMINATED | 16 | 2005-09 |
| NCT00035893 | Phase 2 | COMPLETED | 40 | 2006-08 |
| NCT01545141 | Phase 1 | Phase 2 | TERMINATED | 15 | 2016-04-08 |
| NCT03734692 | Phase 1 | Phase 2 | ACTIVE_NOT_RECRUITING | 24 | 2024-07-01 |
| NCT02432378 | Phase 1 | Phase 2 | TERMINATED | 25 | 2025-06-19 |
| NCT05927142 | Phase 1 | Phase 2 | RECRUITING | 43 | 2026-04 |
| NCT05494697 | Phase 2 | SUSPENDED | 90 | 2029-12 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.